For laboratory research use only. Not for human consumption. All compounds referenced in this article are sold by Explicit SARMs solely as reference materials for in-vitro and animal research by qualified professionals. Nothing here is medical advice, and no statement has been evaluated by the FDA. These materials are not intended to diagnose, treat, cure or prevent any disease.
CJC-1295 and ipamorelin are probably the most commonly paired compounds in growth hormone research catalogs. The reason is mechanistic: they act on two different receptors that both influence pituitary growth hormone release. This overview explains the pairing and what to keep in mind when working with a combined product.
Explicit SARMs supplies the CJC/Ipamorelin 5mg/5mg blend, along with CJC No DAC, CJC DAC and ipamorelin individually, strictly as laboratory reference material.
Two Compounds, Two Receptors
- CJC-1295: a modified GHRH(1-29) analog that acts on the GHRH receptor. It comes in a short-acting form without DAC and a long-acting form with DAC.
- Ipamorelin: a selective pentapeptide GHRP that acts on the ghrelin receptor (GHS-R1a).
- Regulatory status: neither is approved by the FDA for any indication, and both appear on the World Anti-Doping Agency’s prohibited list.
Why Researchers Pair Them
GHRH and ghrelin-receptor signaling are separate inputs to the pituitary, and research on the two classes has long examined how they interact when combined. Pairing a GHRH analog with a selective GHRP is a way to study that interaction while limiting the cortisol and prolactin effects reported with less selective GHRPs. The interaction is the research question. It should not be treated as an established outcome.
Design and Documentation Notes
A fixed 5mg/5mg blend simplifies preparation when that ratio is what the protocol calls for, but it cannot separate the two contributions. Include single-compound arms if attribution matters. Confirm which CJC-1295 form a blend contains, because the DAC and no-DAC versions behave very differently. For more detail, see our CJC-1295 with DAC overview, CJC-1295 without DAC FAQ and ipamorelin overview.
Sourcing and Documentation
Our products come from US domestic manufacturing with three-stage testing: two tests by our manufacturer, then an independent test by Accumark on our behalf. A lot-specific certificate of analysis is available on request through our contact page, and published results are on our lab results page. Record the lot number, COA reference and reconstitution details for every vial.
Frequently Asked Questions
Are CJC-1295 and ipamorelin the same kind of compound?
No. CJC-1295 is a GHRH analog and ipamorelin is a GHRP. They act on different receptors.
Does a COA for a blend need to show both peptides?
Yes. Check that the certificate identifies both components, not just the total peptide content.
Do you provide dosing or usage guidance?
No. The CJC/Ipamorelin blend is sold strictly for laboratory research, and we do not provide dosing, administration or usage guidance.
Ipamorelin on its own is also available as a 15mg/30mL ipamorelin nasal spray.